Metropolitan Life Insurance Company (MetLife)’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio JNCE Stock Details JNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-7,678	Closed	-$64.1K	–	2767
2021 Q4	$64.1K	Sell	7,678 -1,890	-20%	-$15.6K	﹤0.01%	2668
2021 Q3	$71.1K	Buy	+9,568	New	+$59.3K	﹤0.01%	2696
2018 Q2	–	Sell	-5,015	Closed	-$112K	–	2506
2018 Q1	$112K	Buy	+5,015	New	+$111K	﹤0.01%	2234
2017 Q4	–	Sell	-11,093	Closed	-$173K	–	2530
2017 Q3	$173K	Buy	+11,093	New	+$157K	﹤0.01%	2338

Other funds holding JNCE

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s JNCE Position: Q1 2022 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q1 2022, closing a stake of 7,678 shares — an estimated $64.1K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in JNCE in Q3 2017 and held it in 4 quarters. The position peaked at $173K in Q3 2017. 113 funds tracked by Wall St. Rank hold JNCE as of Q1 2022.

Metropolitan Life Insurance Company (MetLife) reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
Metropolitan Life Insurance Company (MetLife) sold 7,678 Jounce Therapeutics, Inc. Common Stock shares in Q1 2022, an estimated $64.1K.
Metropolitan Life Insurance Company (MetLife) first reported a position in Jounce Therapeutics, Inc. Common Stock in Q3 2017 and held it in 4 quarters.
Metropolitan Life Insurance Company (MetLife)'s Jounce Therapeutics, Inc. Common Stock position peaked at $173K in Q3 2017.
113 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q1 2022.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q1 2022, filed 12 May 2022.